Clinical Trial Detail

NCT ID NCT01839955
Title Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Neelesh Sharma MD PhD
Indications

lung non-small cell carcinoma

Therapies

Erlotinib + Quinacrine

Age Groups: adult senior

No variant requirements are available.